Enamine Ltd
9.0/10 Overall Rating
No Reviews Yet
26 Orders Completed
UA
Enamine Ltd was founded in 1991 with the advent of high throughput screening in early drug discovery. The driving force of the company’s development was rapidly increasing demand for new chemical compounds. In over 15 year Enamine has become a world leading provider of Screening Compounds and Building Blocks. It also offers integrated services of custom synthesis, lead optimization and molecular modelling .
The company is committed to providing Life Science industries with wide spectrum of smart chemistry solution to support their efforts in the design of new drugs and other bioactive products.
The body of Enamine, 230 employees, was formed by specialists of leading scientific institutions of Ukraine as well as by talented graduates from Ukrainian universities and institutions. Over 55 scientists of Enamine have been awarded PhD degree and 4 of them have obtained the degree of Doctor of Sciences. Nowadays, Enamine is the largest fine chemicals producer in Ukraine integrating scientific potential and supporting various projects aimed at the development of fundamental research in organic chemistry.
In Enamine, we pay great attention to the development of original and unique chemistry. We believe that diverse techniques and methodologies are the main contributors to drug discovery process. A unique fusion of profound scientific background, cost-efficient work and powerful production facilities makes Enamine a preferred partner in outsourcing different discovery and development projects.
Enamine offers world class service in chemical synthesis of a wide variety of organic compounds on the milligram to kilogram scale at competitive price.
Our In-House Synthetic Chemistry Services
Our Most Frequent Custom Synthesis Requests
How we proceed with your request:
The task is evaluated within a few days to provide you with a quote complemented by a synthetic scheme. The quote is calculated on the basis of the current FTE rate. We deliver detailed biweekly reports with expected delivery dates. Each project is treated under the confidentiality agreement.
We offer comprehensive support in developing your hit compounds. Naturally such programs are realised most efficiently when biological actives originate from our screening collection. However, even if the hit compounds are from the collections of other vendors lead identification and optimization projects can proceed most productively in our hands. Sometimes for this we only need to synthesize first examples of the given chemical series and validate synthesis route.
Re-supply and re-synthesis of hit compounds.
We will help you to assess quality of your hit compounds by pointing out at possible promiscuous structures, frequent hitters, and by revising their analytics in our archive. In most cases we can deliver additional amounts of the hit compounds directly from our stock. Otherwise we can re-synthesize them fairly quickly taking advantage of the chemical procedures and building blocks available in-house. All compounds from our screening collection were designed and synthesized in our laboratories. This means that we possess both knowledge and starting materials to prepare larger batches of the selected compounds within the shortest possible timeframe. Re-synthesis samples will be delivered with certificates of analysis including NMR and LCMS data reports. Upon project finalization we can provide you with detailed chemical procedures to use them in your publications or patent applications.
Compound libraries supplies for hit explosion, lead generation and optimization.
We will be happy to work with you and assist you, as you would need, in design of focused libraries in any phase of your project and provide you with adequate medicinal chemistry support. Usually synthesis of close analogues takes only a few weeks, if not already available on our stock. The compounds, especially in the early lead discovery phase, are delivered on a fixed-price basis implying zero risks on your side: you only pay for the compounds that are delivered according to your exact specifications and the final report provided. In the advanced collaboration phase with dynamically changing synthesis plans it becomes more appropriate to establish an FTE service agreement for several months. Exact duration depends on the nature of the project. Enamine offers most attractive FTE rate in Eastern Europe which, in addition, includes access to the world’s largest inventory of building blocks used in medicinal chemistry. Services for lead generation and optimization can be further supported with CADD and ADME-PK studies of the synthesized compounds directly at Enamine.
We are offering a broad range of in vitro ADMET services, either as separate studies or as value-adding extensions of our in-house biomolecular screening and medicinal chemistry service projects.
The list of standard in vitro ADMET tests includes:
Aqueous compound solubility (nephelometry, filter plate or shake flask protocols, UV or LS-MS-MS detection)
logD/logP (n-octanol:aqueous buffer)
Plasma protein binding (human, rat, mouse), albumin binding
Compound stability in plasma, aqueous buffers, solvents
Microsomal stability (human, rat, mouse)
CYP450 inhibition, major isoforms
PAMPA (GIT and BBB options)
Caco-2 assay
Cytotoxicity studies (HepG2 or other cells)
We are constantly expanding the list of the analytical services offered. In addition, our bioanalytical group can rapidly modify or develop bioanalytical methods according to customer specifications. Pharmacokinetic and toxicity studies in small animals can also be provided. Our bioanalytical laboratory has national regulatory certification for providing bioanalytical support of clinical bioavailability and bioequivalence studies.
The main purpose of the Screening Group is to provide hit identification and hit-to-lead optimization contract services to the biotech and pharmaceutical industry. We are also open to discuss shared-risk exploratory hit finding projects with the industry or academic partners, including the discovery and optimization of various assays and pharmacological tool compounds for new or poorly validated targets.
The HTS Laboratory is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities and the capacity to run both biochemical and cell-based assays in 384-well plate format.
Assay read-out platforms:
Our Protein Thermal Shift Screening Platform (or Differential Scanning Fluorimetry) includes a ViiA 7 System (Applied Biosystems) and two FluoDia T70 (Photal) readers.
The main purpose of the Screening Group is to provide hit identification and hit-to-lead optimization contract services to the biotech and pharmaceutical industry. We are also open to discuss shared-risk exploratory hit finding projects with the industry or academic partners, including the discovery and optimization of various assays and pharmacological tool compounds for new or poorly validated targets.
The HTS Laboratory is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities and the capacity to run both biochemical and cell-based assays in 384-well plate format.
Assay read-out platforms:
Ligand-Based Approach Targeted Libraries (LBA)
Receptor-Based Approach Targeted Libraries (RBA)
Hit Diversified Targeted Libraries (HD)
Cell based HTS assays
Biochemical HTS assays
ADME/DMPK Studies Services
Pharmacology Services
In vivo ADME/DMPK Studies Services
Toxicology Services
Animal Models and Studies Services
Animal Model in vivo Analyses Services
Animal Physiology Analyses Services
Enamine Ltd has not received any reviews.
Enamine Ltd has not received any endorsements.